The sequencing of 3243 patient-derived human adenocarcinoma tumor tissues revealed the following mutations along with their incidence: EGFR (55.9%), KRAS (11.7%), NRAS (0.7%), PIK3CA (2.9%), HER2 (2.1%), BRAF (1.6%); fusions of ALK (2.8%), ROS1 (0.6%), RET (0.6%), and amplifications in MET (1.3%) [7]. This evidence concerns the gene EGFR and adenocarcinoma.